Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine | MicrobiomeTrials← Back to trialsNCT05691530
Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine
CompletedPHASE1INTERVENTIONAL
Trial Details
Start: 2023-03-07Est. Completion: 2025-04-23
Enrollment target: 127 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Dengue Fever
Background:
Some mosquitos carry viruses that can cause disease. Some examples are dengue and Zika. The mosquitos sprea…
Chbar Mon, Kampong Speu, CambodiaCompleted Jan 25, 2022
Rheumatoid Arthritis (RA)Juvenile Idiopathic Arthritis (JIA)Systemic Lupus Erythematosus (SLE)Juvenile Systemic Lupus ErythematosusSystemic Sclerosis (SSc)Idiopathic Inflammatory Myopathies (IIMs)Axial Spondyloarthritis
Psoriatic Arthritis (PsA)
Granulomatosis With Polyangiitis
Microscopic Polyangiitis
Antiphospholipid Syndrome
Takayasu Arteritis
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan…
São Paulo, BrazilEst. completion Dec 30, 2027